The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Patients Lose When Insurance Company Forces Drug Switch

Patients Lose When Insurance Company Forces Drug Switch

April 26, 2018 • By Roy Souaid, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
areeya_ann / shutterstock.com

areeya_ann / shutterstock.com

This past June, a 64-year-old man with a history of psoriatic arthritis and severe arthritis appeared at our clinic for his regular follow-up with concerns about a letter from his insurance company. The letter stated the company wouldn’t pay for the patient’s secukinumab (i.e., Cosentyx) prescription anymore and suggested he take ixekizumab (i.e., Taltz) instead, which the insurer would cover.

You Might Also Like
  • XenoPort’s Psoriasis Drug Found Effective in Phase 2 Trial
  • U.S. Senators Tell Drug Company Execs Pricing Is Morally Repugnant
  • British Columbia Will Be First Canadian Province to Switch Patients to Biosimilars
Explore This Issue
April 2018

The patient had been tolerating secukinumab with no side effects for more than a year. He had previously been maintained on a TNF inhibitor, rituximab, for several years before it lost efficacy and he transitioned to the interleukin (IL) 17 inhibition therapy provided by secukinumab. He’d been stable for the past year without flares or side effects. He’d received his last injection two days prior to presentation. His physical exam was unchanged compared with prior exams, with no significant active/new skin lesions or joint effusions or bony spurs/erosions.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The proposed new agent works similar to IL-17, but there was no medical indication to attempt a different agent because the patient had been stable and benefiting from secukinumab therapy. Exposing the patient to a new agent would be unnecessary and potentially dangerous.

What Now?

What would most providers do next? Switch drugs, or file an appeal? Most file an appeal and attempt to pressure the insurance company to cover the current drug. We attempted to obtain such an approval. After two months, we finally obtained a discussion with the insurance company experts. It wasn’t fruitful, and the discussion wasn’t patient focused. The expert tried to justify treating the patient with a different agent as being more cost effective, which was irrelevant in this case because there’s no moral or medical reason to expose someone to a different class of biological medication if they’ve been stable on a different agent.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Sadly, insurance companies can change medication coverage at any point by making deals with competing drug companies. This might not be terrible when the medication is the same, such as different brands of aspirin. When it comes to biological agents, such as IL-17 inhibitors, though, a change between different manufacturers is a change between agents, and we all know these agents aren’t similar.

Even worse? Ixekizumab wasn’t even FDA approved to treat the patient’s condition at the time! Ixekizumab didn’t receive FDA approval to treat psoriatic arthritis until December 2017. At the time the insurance company suggested the switch, it was FDA approved only for plaque psoriasis treatment. Of course, secukinumab was FDA approved for psoriasis, ankylosing spondylitis and psoriatic arthritis.

Pages: 1 2 | Single Page

Filed Under: Ethics, Opinion Tagged With: Health Insurance, prescriptionIssue: April 2018

You Might Also Like:
  • XenoPort’s Psoriasis Drug Found Effective in Phase 2 Trial
  • U.S. Senators Tell Drug Company Execs Pricing Is Morally Repugnant
  • British Columbia Will Be First Canadian Province to Switch Patients to Biosimilars
  • Drug Company Gifts Linked to Doctors’ Prescribing Habits

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)